Esketamine
- Generic Name
- Esketamine
- Brand Names
- Spravato
- Drug Type
- Small Molecule
- Chemical Formula
- C13H16ClNO
- CAS Number
- 33643-46-8
- Unique Ingredient Identifier
- 50LFG02TXD
- Background
Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
...
- Indication
Esketamine is indicated in combination with an oral antidepressant for the treatment of treatment-resistant depression in adults. It is also indicated for the treatment of depressive symptoms in adults with major depressive disorder experiencing acute suicidal ideation or behaviour.
- Associated Conditions
- Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Pain
- Associated Therapies
- Intubation
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath